iSpecimen Q1 revenue down 22% to $2.29M; net loss widens to ($0.32)/share

iSpecimen Inc.

2024-Q1 EPS reported -$0.32 vs consensus -$220.32 ▲ beat (+99.9%)

Revenue $2.29M vs $2.95M YoY; specimen count fell 39% to 5,241, offset by 28% higher ASP ($437).
Net loss $2.90M ($0.32/share) vs $2.43M loss ($0.27/share) in Q1 2023; G&A up 16% to $2.10M.
Cash and securities $2.56M at Mar 31, down from $5.01M at Dec 31, 2023; ATM offering up to $1.5M.
Next Day Quotes reached 40% of all quotes; conversion rate on NQ quotes hit 91% (vs 32% in Q4 2023).
Supplier network trimmed to 140 from 243; customer count grew to 600+ (up 66 YoY).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

iSpecimen Inc. reported for the quarter ended March 31, 2024 results: revenue approximately $2.29 million, net income approximately $2.90 million, EPS ($0.32) per share.

Period: for the quarter ended March 31, 2024
Revenue: approximately $2.29 million
Net income: approximately $2.90 million
EPS: ($0.32) per share
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2024, revenue was approximately $2.29 million, compared to approximately $2.95 million for the quarter ended March 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

iSpecimen Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-057770

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.